Chromogenic <i>in situ</i> hybridization for Her‐2/neu‐oncogene in breast cancer: comparison of a new dual‐colour chromogenic <i>in situ</i> hybridization with immunohistochemistry and fluorescence <i>in situ</i> hybridization

Abstract excerpt

AIMS: Her-2/neu testing is used as a marker for Herceptin therapy. The aim was to investigate new dual-colour chromogenic in situ hybridization (CISH), in a large number of breast carcinomas (n = 205) with DNA-specific dual-colour probes (ZytoVision, Bremerhaven, Germany) and to compare the results with immunohistochemistry (n = 205) and fluorescence in situ hybridization (FISH) (n = 129). METHODS AND RESULTS:...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Cancer Treatment Studies
• Share to Breast Lesions and Carcinomas